scholarly journals Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

2021 ◽  
Vol 9 (2) ◽  
Author(s):  
María L. Formica ◽  
Hamoudi G. Awde Alfonso ◽  
Santiago D. Palma
Keyword(s):  
Drug Therapy ◽  
Ocular Angiogenesis ◽  
Biological Drug ◽  
Anti Vegf

scholarly journals A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis

2012 ◽  
Vol 181 (2) ◽  
pp. 376-379 ◽  
Author(s):  
Leo A. Kim ◽  
Patricia A. D'Amore
Keyword(s):  
Ocular Angiogenesis ◽  
Anti Vegf ◽  
History Of

scholarly journals Anti-VEGF Therapy and the Retina: An Update

2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
Vikas Tah ◽  
Harry O. Orlans ◽  
Jonathan Hyer ◽  
Edward Casswell ◽  
Nizar Din ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Visual Outcome ◽  
Retinal Diseases ◽  
Ocular Angiogenesis ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Sight Loss ◽  
Endothelial Growth Factor ◽  
The Impact

Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.

scholarly journals Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Kenichi Kimoto ◽  
Toshiaki Kubota
Keyword(s):  
Intravitreal Injection ◽  
Neovascular Glaucoma ◽  
Therapeutic Window ◽  
Panretinal Photocoagulation ◽  
Drug Trials ◽  
Ocular Angiogenesis ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Stage 4 ◽  
Treatment Paradigm

We review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti-VEGF antibodies, and also evaluating their outcomes. Intraocular injections of anti-VEGF drug are considered to be an effective treatment for macular edema after retinal vein occlusion, however, recurrent/persistent edema is common. The recent reports may lead to a shift in treatment paradigm for DME, from laser photocoagulation, to newer approaches using anti-VEGF drugs. There have been several well-publicized prospective, randomized studies that demonstrated the efficacy of intravitreal injection of anti-VEGF drugs for patients with AMD. Adjuvant bevacizumab for neovascular glaucoma may prevent further PAS formation, and it is likely to open up a therapeutic window for a panretinal photocoagulation and trabeculectomy. Intravitreal injection of bevacizumab (IVB) results in a substantial decrease in bleeding from the retinal vessels or new vessels during a standard vitrectomy. IVB has also been reported to be effective for inducing the regression of new vessels in proliferative diabetic retinopathy. The use of bevacizumab in stage 4 or 5 retinopahty of permaturity (ROP) is to reduce the plus sign to help reduce hemorrhage during the subsequent vitrectomy. Some authors reported cases of resolution of stage 4 A ROP after bevacizumab injection.

scholarly journals Largazole Inhibits Ocular Angiogenesis by Modulating the Expression of VEGFR2 and p21

Marine Drugs ◽  
2021 ◽  
Vol 19 (8) ◽  
pp. 471
Author(s):  
Beiying Qiu ◽  
Alison Tan ◽  
Yu Zhi Tan ◽  
Qi-Yin Chen ◽  
Hendrik Luesch ◽  
...  
Keyword(s):  
Vascular Endothelial Cells ◽  
Vascular Endothelial Cell ◽  
Vascular Endothelial ◽  
Ocular Angiogenesis ◽  
Anti Vegf ◽  
Metatarsal Bones ◽  
Number Of Patients ◽  
Choroidal Vasculature ◽  
Characteristic Features

Ocular angiogenic diseases, characterized by abnormal blood vessel formation in the eye, are the leading cause of blindness. Although Anti-VEGF therapy is the first-line treatment in the market, a substantial number of patients are refractory to it or may develop resistance over time. As uncontrolled proliferation of vascular endothelial cells is one of the characteristic features of pathological neovascularization, we aimed to investigate the role of the class I histone deacetylase (HDAC) inhibitor Largazole, a cyclodepsipeptide from a marine cyanobacterium, in ocular angiogenesis. Our study showed that Largazole strongly inhibits retinal vascular endothelial cell viability, proliferation, and the ability to form tube-like structures. Largazole strongly inhibits the vessel outgrowth from choroidal explants in choroid sprouting assay while it does not affect the quiescent choroidal vasculature. Largazole also inhibits vessel outgrowth from metatarsal bones in metatarsal sprouting assay without affecting pericytes coverage. We further demonstrated a cooperative effect between Largazole and an approved anti-VEGF drug, Alflibercept. Mechanistically, Largazole strongly inhibits the expression of VEGFR2 and leads to an increased expression of cell cycle inhibitor, p21. Taken together, our study provides compelling evidence on the anti-angiogenic role of Largazole that exerts its function through mediating different signaling pathways.

FRI0253 Biological Drug Therapy Prioritization Protocol as A Tool to Improve the Cost-Effectiveness Usage of Biological Drugs in Rheumatoid Arthritis Patients

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 475.1-475
Author(s):  
J. Borras-Blasco ◽  
D.-E. Casterá ◽  
F.J. Abad ◽  
J.D. Rosique-Robles
Keyword(s):  
Rheumatoid Arthritis ◽  
Cost Effectiveness ◽  
Drug Therapy ◽  
Biological Drugs ◽  
Biological Drug ◽  
The Cost

scholarly journals Evaluation of ppd response in patients with idiopathic arthritis who are on biological drug therapy

2014 ◽  
Vol 12 (S1) ◽  
Author(s):  
Kenan Barut ◽  
Muhammet Köşker ◽  
Tugba Erener-Ercan ◽  
Haluk Cokugras ◽  
Yildiz Camcioglu ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Biological Drug

Does eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy reduce the long-term risk of ulcers? A double-blinded randomized trial

2001 ◽  
Vol 120 (5) ◽  
pp. A143-A143
Author(s):  
F CHAN ◽  
K TO ◽  
J WU ◽  
W LEUNG ◽  
Y LEE ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Drug Therapy ◽  
Randomized Trial ◽  
Inflammatory Drug ◽  
Anti Inflammatory ◽  
Double Blinded
Sign in / Sign up

Export Citation Format

Share Document